|
1) Hadden RD, Cornblath DR, Hughes RA, et al. Electrophysiological classification of Guillain-Barre syndrome: clinical associations and outcome. Plasma Exchange/Sandoglobulin Guillain-Barre Syndrome Trial Group. Ann Neurol. 1998; 44: 780-8
|
|
|
|
2) Albers JW, Donofrio PD, McGonagle TK. Sequential electrodiagnostic abnormalities in acute inflammatory demyelinating polyradiculoneuropathy. Muscle Nerve. 1985; 8: 528-39
|
|
|
|
|
|
3) Asbury AK. Diagnostic considerations in Guillain-Barre syndrome. Ann Neurol. 1981; 9 Suppl: 1-5
|
|
|
|
|
|
4) Ho TW, Mishu B, Li CY, et al. Guillain-Barre syndrome in northern China. Relationship to Campylobacter jejuni infection and anti-glycolipid antibodies. Brain. 1995; 118: 597-605
|
|
|
|
|
|
5) The Italian Guillain-Barre Study Group. The prognosis and main prognostic indicators of Guillain-Barre syndrome. A multicentre prospective study of 297 patients. Brain. 1996; 119: 2053-61
|
|
|
|
|
|
6) Meulstee J, van der Meche FG. Electrodiagnostic criteria for polyneuropathy and demyelination: application in 135 patients with Guillain-Barre syndrome. Dutch Guillain-Barre Study Group. J Neurol Neurosurg Psychiatry. 1995; 59: 482-6
|
|
|
|
|
|
7) Austin JH. Recurrent polyneuropathies and their corticosteroid treatment; with five-year observations of a placebo-controlled case treated with corticotrophin, cortisone, and prednisone. Brain. 1958; 81: 157-92
|
|
|
|
|
|
8) Dyck PJ, Lais AC, Ohta M, et al. Chronic inflammatory polyradiculoneuropathy. Mayo Clin Proc. 1975; 50: 621-37
|
|
|
|
|
|
9) Albers JW, Kelly JJ, Jr. Acquired inflammatory demyelinating polyneuropathies: clinical and electrodiagnostic features. Muscle Nerve. 1989; 12: 435-51
|
|
|
|
|
|
10) Barohn RJ, Kissel JT, Warmolts JR, et al. Chronic inflammatory demyelinating polyradiculoneuropathy. Clinical characteristics, course, and recommendations for diagnostic criteria. Arch Neurol. 1989; 46: 878-84
|
|
|
|
|
|
11) Research criteria for diagnosis of chronic inflammatory demyelinating polyneuropathy (CIDP). Report from an Ad Hoc Subcommittee of the American Academy of Neurology AIDS Task Force. Neurology. 1991; 41: 617-8
|
|
|
|
|
|
12) Hughes R, Bensa S, Willison H, et al. Randomized controlled trial of intravenous immunoglobulin versus oral prednisolone in chronic inflammatory demyelinating polyradiculoneuropathy. Ann Neurol. 2001; 50: 195-201
|
|
|
|
|
|
13) Saperstein DS, Katz JS, Amato AA, et al. Clinical spectrum of chronic acquired demyelinating polyneuropathies. Muscle Nerve. 2001; 24: 311-24
|
|
|
|
|
|
14) Nicolas G, Maisonobe T, Le Forestier N, et al. Proposed revised electrophysiological criteria for chronic inflammatory demyelinating polyradiculoneuropathy. Muscle Nerve. 2002; 25: 26-30
|
|
|
|
|
|
15) Thaisetthawatkul P, Logigian EL, Herrmann DN. Dispersion of the distal compound muscle action potential as a diagnostic criterion for chronic inflammatory demyelinating polyneuropathy. Neurology. 2002; 59: 1526-32
|
|
|
|
|
|
16) Van den Bergh PY, Pieret F. Electrodiagnostic criteria for acute and chronic inflammatory demyelinating polyradiculoneuropathy. Muscle Nerve. 2004; 29: 565-74
|
|
|
|
|
|
17) European Federation of Neurological Societies/Peripheral Nerve Society Guideline on management of chronic inflammatory demyelinating polyradiculoneuropathy. Report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society. J Peripher Nerv Syst. 2005; 10: 220-8
|
|
|
|
|
|
18) European Federation of Neurological Societies/Peripheral Nerve Society Guideline on management of paraproteinemic demyelinating neuropathies. Report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society. J Peripher Nerv Syst. 2006; 11: 9-19
|
|
|
|
|
|
19) European Federation of Neurological Societies/Peripheral Nerve Society Guideline on management of chronic inflammatory demyelinating polyradiculoneuropathy: report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society--First Revision. J Peripher Nerv Syst. 2010; 15: 1-9
|
|
|
|
|
|
20) Koski CL, Baumgarten M, Magder LS, et al. Derivation and validation of diagnostic criteria for chronic inflammatory demyelinating polyneuropathy. J Neurol Sci. 2009; 277: 1-8
|
|
|
|
|
|
21) Mehndiratta MM, Hughes RA, Agarwal P. Plasma exchange for chronic inflammatory demyelinating polyradiculoneuropathy. Cochrane Database Syst Rev. 2004; (3): CD003906
|
|
|
|
|
|
22) Dyck PJ, OʼBrien PC, Oviatt KF, et al. Prednisone improves chronic inflammatory demyelinating polyradiculoneuropathy more than no treatment. Ann Neurol. 1982; 11: 136-41
|
|
|
|
|
|
23) van Doorn PA, Brand A, Strengers PF, et al. High-dose intravenous immunoglobulin treatment in chronic inflammatory demyelinating polyneuropathy: a double-blind, placebo-controlled, crossover study. Neurology. 1990; 40: 209-12
|
|
|
|
|
|
24) Hahn AF, Bolton CF, Pillay N, et al. Plasma-exchange therapy in chronic inflammatory demyelinating polyneuropathy. A double-blind, sham-controlled, cross-over study. Brain. 1996; 119: 1055-66
|
|
|
|
|
|
25) Dyck PJ, Daube J, OʼBrien P, et al. Plasma exchange in chronic inflammatory demyelinating polyradiculoneuropathy. N Engl J Med. 1986; 314: 461-5
|
|
|
|
|
|
26) Dyck PJ, Litchy WJ, Kratz KM, et al. A plasma exchange versus immune globulin infusion trial in chronic inflammatory demyelinating polyradiculoneuropathy. Ann Neurol. 1994; 36: 838-45
|
|
|
|
|
|
27) Hughes RA, Swan AV, van Doorn PA. Cytotoxic drugs and interferons for chronic inflammatory demyelinating polyradiculoneuropathy. Cochrane Database Syst Rev. 2004: CD003280
|
|
|
|
|
|
28) Kuitwaard K, van Doorn PA. Newer therapeutic options for chronic inflammatory demyelinating polyradiculoneuropathy. Drugs. 2009; 69: 987-1001
|
|
|
|
|
|
29) Marsh EA, Hirst CL, Llewelyn JG, et al. Alemtuzumab in the treatment of IVIG-dependent chronic inflammatory demyelinating polyneuropathy. J Neurol. 2010; 257: 913-9
|
|
|
|
|
|
30) Randomised controlled trial of methotrexate for chronic inflammatory demyelinating polyradiculoneuropathy (RMC trial): a pilot, multicentre study. Lancet Neurol. 2009; 8: 158-64
|
|
|
|
|
|
31) Ruts L, Drenthen J, Jacobs BC, et al. Distinguishing acute-onset CIDP from fluctuating Guillain-Barre syndrome: a prospective study. Neurology. 2010; 74: 1680-6
|
|
|
|
|
|
32) Ruts L, van Koningsveld R, van Doorn PA. Distinguishing acute-onset CIDP from Guillain-Barre syndrome with treatment related fluctuations. Neurology. 2005; 65: 138-40
|
|
|
|
|
|
33) Dionne A, Nicolle MW, Hahn AF. Clinical and electrophysiological parameters distinguishing acute-onset chronic inflammatory demyelinating polyneuropathy from acute inflammatory demyelinating polyneuropathy. Muscle Nerve. 2010; 41: 202-7
|
|
|
|
|
|
34) Comi C, Osio M, Ferretti M, et al. Defective Fas-mediated T-cell apoptosis predicts acute onset CIDP. J Peripher Nerv Syst. 2009; 14: 101-6
|
|
|
|
|
|
35) Iijima M, Yamamoto M, Hirayama M, et al. Clinical and electrophysiologic correlates of IVIg responsiveness in CIDP. Neurology. 2005; 64: 1471-5
|
|
|
|
|
|
36) Iijima M, Koike H, Hattori N, et al. Prevalence and incidence rates of chronic inflammatory demyelinating polyneuropathy in the Japanese population. J Neurol Neurosurg Psychiatry. 2008; 79: 1040-3
|
|
|
|
|
|
37) Iijima M, Tomita M, Morozumi S, et al. Single nucleotide polymorphism of TAG-1 influences IVIg responsiveness of Japanese patients with CIDP. Neurology. 2009; 73: 1348-52
|
|
|
|
|
|
38) Kuitwaard K, de Gelder J, Tio-Gillen AP, et al. Pharmacokinetics of intravenous immunoglobulin and outcome in Guillain-Barre syndrome. Ann Neurol. 2009; 66: 597-603
|
|
|
|
|
|
39) Tackenberg B, Jelcic I, Baerenwaldt A, et al. Impaired inhibitory Fcgamma receptor IIB expression on B cells in chronic inflammatory demyelinating polyneuropathy. Proc Natl Acad Sci U S A. 2009; 106: 4788-92
|
|
|
|
|
|
40) Tackenberg B, Nimmerjahn F, Linemann JD. Mechanism of IVIG efficacy in chronic inflammatory demyelinating polyneuropathy. J Clin Immunol. 2010; 30 Suppl 1: S65-9
|
|
|
|
|